Clinical relapse · patients with Crohn's disease (mixed disease activity population with clinical response at baseline)
Infliximab probably leads to lower clinical relapse (at 30‐32 weeks, CDAI > 150) compared with placebo (moderate certainty).
1 finding from 1 review
Loss of clinical response · Participants with Crohn's disease in remission
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · Participants with Crohn's disease in remission
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (at 2 years) · Participants with Crohn's disease in remission
It is very uncertain whether infliximab changes serious adverse events (at 2 years) compared with purine analogues (very low certainty).
1 finding from 1 review
Clinical relapse · patients with Crohn's disease (with mixed/low disease activity at baseline)
Infliximab showed no clear difference in clinical relapse (at 52 weeks, HBI > 4) compared with biosimilar (low certainty).
1 finding from 1 review
Loss of clinical response (at 52 weeks, HBI change from baseline of less than 4 points and a total score of less than 7 points) · patients with Crohn's disease (with mixed/low disease activity at baseline)
Infliximab may leads to higher loss of clinical response (at 52 weeks, HBI change from baseline of… compared with biosimilar (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with Crohn's disease (with mixed/low disease activity at baseline)
Infliximab may leads to higher withdrawal due to adverse events (at 52 weeks) compared with biosimilar (low certainty).
1 finding from 1 review
Serious adverse events (at 52 weeks) · patients with Crohn's disease (with mixed/low disease activity at baseline)
Infliximab showed no clear difference in serious adverse events (at 52 weeks) compared with biosimilar (low certainty).
1 finding from 1 review
Loss of clinical response (at 22 weeks, less than 100 points in CDAI change) · patients with Crohn's disease (mixed disease activity population with clinical response at baseline)
It is very uncertain whether infliximab changes loss of clinical response (at 32 weeks, less than 70 points in CDAI… compared with placebo (very low certainty).
1 finding from 1 review
Clinical relapse · patients with Crohn's disease (active disease population with clinical response at baseline)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Loss of clinical response (at 22 weeks, less than 100 points in CDAI change) · patients with Crohn's disease (active disease population with clinical response at baseline)
It is very uncertain whether infliximab changes loss of clinical response (at 56 weeks, less than 100 points in CDAI… compared with adalimumab (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with Crohn's disease (active disease population with clinical response at baseline)
It is very uncertain whether infliximab changes withdrawal due to adverse events (at 56 weeks) compared with adalimumab (very low certainty).
1 finding from 1 review
Serious adverse events (at 56 weeks) · patients with Crohn's disease (active disease population with clinical response at baseline)
It is very uncertain whether infliximab changes serious adverse events (at 56 weeks) compared with adalimumab (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with Crohn's disease (mixed disease activity population with clinical response at baseline)
It is very uncertain whether infliximab changes withdrawal due to adverse events (at 32‐54 weeks) compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events (at 54 weeks) · patients with Crohn's disease (mixed disease activity population with clinical response at baseline)
It is very uncertain whether infliximab changes serious adverse events (at 54 weeks) compared with placebo (very low certainty).
1 finding from 1 review
Clinical relapse · Participants with Crohn's disease in remission
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Improved IBDQ at week 8 · people with active UC
Infliximab leads to higher improved IBDQ at week 8 compared with placebo (high certainty).
1 finding from 1 review
IBDQ at week 6 · people with active UC
1 finding from 1 review
EQ‐5D at week 6 · people with active UC
1 finding from 1 review
Health‐related quality of life · people with active UC
Infliximab probably leads to higher improved SF‐36 PCS at week 8 compared with placebo (moderate certainty).
1 finding from 1 review